TP53 encodes the p53 protein, a critical tumor suppressor that acts as a transcription factor to protect cells from damage. When activated by cellular stress such as DNA damage, p53 triggers responses including DNA repair, cell cycle arrest, and programmed cell death (apoptosis) to prevent the propagation of damaged cells. TP53 is the most frequently mutated gene in human cancers, and loss of its function contributes to tumor development, invasion, drug resistance, and genomic instability. Inherited mutations in TP53 cause Li-Fraumeni syndrome, a rare hereditary condition that greatly increases the risk of developing multiple types of cancer at a young age.

TP53 mutations cause Li-Fraumeni syndrome, a hereditary cancer predisposition, so the interpretation of splice-site variants in this gene directly affects cancer-risk assessment. This variant is classified as Uncertain Significance: it is exceptionally rare in population databases, but no functional, de novo, or family-segregation evidence currently establishes whether it disrupts p53's tumor-suppressor function. Additional clinical or functional data would be needed to determine whether it contributes to cancer risk.